The AI Forensics Play Reporting Q2 Earnings This Thursday

Wall Street missed this pivot, but the buyers with September budgets to burn didn't.

August 10, 2026

Federal fiscal year-end is closing fast, and one under-covered name sits right in the middle of that order flow, with earnings three days out. Classic government-contractor discount on what's turning into a subscription software business.

Don't miss (Sponsored)

While many investors remain focused on AI and high-profile tech stocks, a different market trend is quietly gaining momentum.

One experienced researcher has released a free briefing explaining what's driving the shift and how investors may be able to position themselves as it unfolds.

See the Full Story

Cellebrite DI (NASDAQ: CLBT) is the Israel-based digital intelligence platform that helps police, prosecutors, and federal agencies pull and investigate data off phones, drones, and cloud accounts.

Market cap is right around $4B. Mark your calendar: Q2 earnings hit before the open on Thursday, August 13, with the call at 8:30 a.m. ET.

A month before the print, Cellebrite expanded an exclusive partnership that materially widens what the platform can do. Drone forensics. AI-driven cloud investigations. And a customer list stacked with federal law enforcement.

Here's why this one is on my desk today. You're getting a shot at entering before the print, into a name where the story is shifting from "government contractor" to AI-enabled SaaS platform. Those two things trade at very different multiples.

Action: Accumulate between $15.50 and $16.50 ahead of the August 13 Q2 print and the follow-on federal contract cycle in Q4.

What Just Happened

On July 8, Cellebrite expanded its partnership with SkySafe to deepen its drone forensics capability. Sounds niche. It isn't.

Drones now show up at nearly every kind of investigation you can name, from border enforcement to organized crime to critical-infrastructure incidents.

Being the vendor that can pull evidence off a seized drone the way agents already pull it off a seized phone is a real competitive moat.

Layer that on top of what Cellebrite has already been doing with its AI cloud investigation suite, and you get a company turning itself into the default forensics stack for federal, state, and local agencies.

That's not a one-off. It's a pattern.

Tech Edge (Sponsored)

First users could have already grown their money dramatically every single year this AI has been running, based on the average winning trades it uncovers – WITHOUT following market news, WITHOUT watching central banks, and WITHOUT the stress most traders deal with daily.

For a limited time, you can try this AI yourself, completely free – no email, no credit card needed.

Operational Overview and Recent Earnings

Digital intelligence platforms let investigators pull data off locked devices, run analytics against it, and share findings across a case file. Cellebrite's DI product is the toolkit sitting behind almost every major digital investigation in the Western world.

The company also runs a growing cloud investigation product that pulls evidence from accounts, apps, and now drones, so you're looking at a business embedded in modern police work.

The customer base skews heavily toward US federal agencies, state and local law enforcement, and allied governments. That's a very sticky, high switching-cost buyer. Once your workflow runs on Cellebrite, you don't rip it out.

Action: Take a starter position pre-print, then size up on a clean subscription growth and FCF beat. Track Thursday's Q2 release for subscription ARR growth, gross margin, and free cash flow. Those are the three lines that reprice your stock.

NYC Signals More (Sponsored)

Last year I ran for Mayor of New York City... and lost to a 34-year-old Democratic Socialist.

Now he wants to spend $70 million just to study government-run grocery stores.

Raise property taxes 9.5%.

And hike taxes on every corporation and high earner.

I've spent 30 years on Wall Street.

And I'm convinced what's starting in New York is just the beginning.

I've put together a free analysis explaining exactly what's coming, and what you can do about it.

Read it here.

Drone Forensics and Federal AI Spend Are a Long-Term Growth Catalyst

Cellebrite's expanded SkySafe partnership plugs directly into a revenue pool that barely existed five years ago.

Drones have gone from novelty to routine evidence, and agencies are now writing procurement lines for drone forensics tooling that didn't exist in their last budget. You want exposure to this before that spend cycle actually hits the P&L.

Federal law enforcement budgets are also shifting toward AI-enabled tools that can process case backlogs faster. Cellebrite's cloud investigation product is built exactly for that. When agencies get their AI line items funded, this is the kind of vendor you'll see getting called.

The subscription mix keeps climbing. The company has been converting one-time license buyers into recurring SaaS customers, and you can see it running on that line.

Software gross margins here run well above the hardware line. A real SaaS margin profile, not a services business dressed up as one. Free cash flow is already positive.

Every point of ARR mix shift compresses the "lumpy contractor" discount the market is still applying. If Thursday holds the trajectory, the discount the market is applying gets a lot harder to justify.

Action: Watch the Q2 call for AI cloud investigation ARR disclosure. If management quantifies AI product revenue, that's the moment the SaaS narrative becomes undeniable.

Bear Case

Any name with heavy US federal exposure trades with a discount for contract timing lumpiness. A continuing resolution or short-term shutdown pushes contracts to the right and hits the growth line directly.

The stock still gets valued more like a defense contractor than a software company. That's your opportunity, but also your risk. One weak subscription quarter and the "lumpy contractor" narrative snaps right back, and the multiple with it.

Coverage on this name is thin compared to the big SaaS names, which means less price support on a miss.

Cellebrite is Israel-based, which introduces headline risk you don't get with a Palo Alto-headquartered peer. Institutional buyers occasionally pause here for that reason alone.

The customer base includes agencies whose use of these tools sometimes ends up in the news. That's an ESG overhang that keeps some funds on the sidelines.

Magnet Forensics and Grayshift are the closest peers, and any of the big security platforms could decide to build or buy their way into forensics.

Action: Hedge with a broader cybersecurity ETF or a larger platform peer to shield against the Israel and ESG headline risk while keeping your forensics exposure.

If you're growth-focused, consider a smaller basket that pairs CLBT with a pure-play SaaS name to smooth the federal timing lumpiness.

The SaaS Transition Changes How This Gets Valued

A clean Q2 print, with subscription ARR accelerating, gross margins holding, and FCF expanding, reprices the stock right there.

Federal fiscal year-end is September 30, and the order flow that hits Cellebrite's book in September and October is what shapes 2027 guidance. Watch for contract announcements in that window.

Starter position ahead of the print, between $15.50 and $16.50, is your "get on the board" tranche. Add on a clean beat, ideally on any first-session or second-session dip.

If you already own it, trim on a 15%+ spike into the print and reload after. Don't let a one-day rip take you out of a multi-quarter thesis.

Setup Scorecard

Entry Zone: $15.50 to $16.50

Target: $18

Stop Loss: Reassess below $14 or on a subscription-ARR miss

Catalyst Timeline: Q2 earnings August 13; US federal Q4 contract cycle September-October; AI product ARR disclosure on the call

Confidence Level: Medium. Strong setup and clear catalyst, but thin coverage and federal timing lumpiness keep this from being a High conviction call.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any tech stocks you want me to check out.

Best Regards,
—Noah Zelvis
Tech Stock Insider